Alimera Sciences (NASDAQ:ALIM) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Alimera Sciences (NASDAQ:ALIM) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Yahoo Finance reports. Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The firm had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million.

Alimera Sciences Stock Performance

ALIM stock traded up $0.02 during trading on Friday, hitting $5.57. The company had a trading volume of 13,214 shares, compared to its average volume of 210,894. The firm has a market cap of $291.81 million, a PE ratio of -3.55 and a beta of 1.28. Alimera Sciences has a 1-year low of $2.61 and a 1-year high of $5.65. The firm has a 50-day moving average price of $4.76 and a 200-day moving average price of $4.02. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ALIM shares. StockNews.com started coverage on Alimera Sciences in a report on Monday. They issued a “hold” rating for the company. Maxim Group reissued a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. HC Wainwright downgraded Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price for the company. in a report on Tuesday, June 25th. Finally, Alliance Global Partners restated a “neutral” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).